T-Therapeutics
Last verified 2026-04-30. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $29.7Mattributed |
|---|---|
| Latest round | series-a, $29.7M, 2025-11-01attributed |
| Founded | unknown |
| Headquarters | Cambridge |
| Industry | bio |
| Stage | series-a |
| Website | t-therapeutics.com |
T-Therapeutics is a Cambridge, UK biopharmaceutical company developing T cell therapies for cancer and autoimmune disease via its proprietary OpTiMus TCR platform. It serves patients with solid tumors and autoimmune conditions of high unmet need. The platform finds fully human receptors that reach once-undruggable intracellular targets.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-11-01 | series-a | $29.7M | undisclosed |
Detected tech stack
Nginx, WordPress 7.0, Lenis 1.1.13, Yoast SEO 27.6, Google Analytics, Google Tag Manager, Slider Revolution, jQuery Migrate 3.4.1, imagesLoaded 4.1.4, parallax.js, PHP, DoubleClick Floodlight
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $29.7M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $29.7M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | t-therapeutics.com, read 2026-04-30 |
| Description | self-reported | t-therapeutics.com, read 2026-04-30 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.